Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-LUNG-Timing: Time-of-day serplulimab plus chemotherapy as neoadjuvant therapy for stage II–IIIb NSCLC
ChiCTR2600121500Phase 3Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of serplulimab in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Tangdu Hospital. Primary endpoint: pathological complete response (pCR). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600121500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121500.